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Conclusions: Patients with a history of IHD do not call earlier than IHD-
naïve patients when they are confronted with symptoms of AMI. Cardiologists
should spend more time to educate their coronary patients to recognize symp-
toms of AMI.
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12-weeks of lipid-lowering therapy decrease exercise tolerance
without affecting endothelial function or arterial stiffness among sub-
jects with primary untreated hypercholesterolemia
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Purpose: Conduit vessel non-compliance and endothelial dysfunction may
be manifestations of a similar process which lead to atherosclerosis. Statin
therapy may have beneficial effects on these parameters, despite adverse effects
on muscle function. We sought to study the effect of statin therapy on endothe-
lial function, aortic stiffness, and their potential impact on exercise tolerance.
Methods: In this double-blind, placebo-controlled trial, 22 patients with
primary untreated hypercholesterolemia and free of other risk factors or car-
diovascular disease (56±9 years, 12 men, BMI: 27±4 kg.m-2, blood pressure:
127/79±12/5 mmHg) were randomized 1:1 to placebo or pravastatin 40 mg
daily for 12 weeks. Endothelial function (ultrasound-guided brachial artery
flow mediated dilatation (FMD)), aortic stiffness (tonometry-derived carotid-
femoral pulse wave velocity (cfPWV)), and submaximal and maximal exer-
cise tolerance were measured.
Results: Despite a significant reduction in total and LDL-cholesterol in the
treatment group (total-cholesterol: 6.18±0.94 vs. 5.23±0.79 mmol.L-1, P=0.03;
LDL: 4.15±0.72 vs. 3.03±0.73 mmol.L-1, P=0.005 in placebo and treatment
groups respectively), no between-group differences were observed for
endothelial function (FMD: 10.05±4.73 vs. 9.23±2.90%, P=0.8), vascular
compliance (cfPWV: 8.50±2.07 vs. 8.65±2.12 m.s-1, P=0.9), submaximal (sub-
maximal exercise time: 1229±862 vs. 1561±948 sec, P=0.5), or maximal exer-
cise tolerance (VO2 peak: 25.59±4.60 vs. 28.93±9.62 mL.min-1.kg-1, P=0.7).
However, we observed in pre/post comparisons, a significant decrease in VO2
peak in the statin group (29.07±6.20 vs. 25.59±4.60 mL.min-1.kg-1, P=0.008)
and an improvement in VO2 peak in the placebo group (26.86±9.00 vs.
28.93±9.62 mL.min-1.kg-1, P=0.005).
Conclusion: In patients with previously untreated hypercholesterolemia,
12-weeks of statin therapy had no effect on endothelial function or arterial
stiffness, but had deleterious effects on maximal exercise tolerance.
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Multimedia cardiologic personal medical record on secure smart-
phones or tablets, obtained by a European cross-border eHealth
service based on an interoperability platform
Isaac Azancot
Hôpital Lariboisière, Cardiologie, Paris, France
The need for exchanging medical information becomes – for health care
coordination as well as for pooling research protocols – a growing need in
patients with serious cardiologic diseases requiring European mobility. This
need is facing difficulty to combine in Europe on a single medium documents
and dynamic images from hospital health systems, due to the lack of a single
European health identifier and to delays in setting up an effective standardiza-
tion of exchanges in most of the European facilities and health institutions.
The technologies used in this project are based on a server (“Access Box”)
set up in any European Partner Hospital (EPH), allowing for any patient
requiring access to this service, and volunteer: 
1/ to initiate the process inside the EPH from a smartphone or a tablet
assigned to the patient. The device is identified through a SDI (Single Device
Identifier), and the patient through a biometric (facial or fingerprint) recogni-
tion algorithm and a password; 
2/ to collect from the Access Box documents, structured information and
images (static and dynamic)  included in the EPH information system and
DICOM servers; 
3/ to convert them into a transport (IHE – XDS) and exchange (CDA – R2)
format, conforming to international medical interoperability standards; 
4/ to transfer, on the basis of a reconciliation between the SDI table and the
local patient health identifier of each EPH:
– documents to a “Document Repository” and images to a “DICOM Image
Repository” hosted by an accredited heath data webhost
– structured metadata to a pointers server integrating a relational database.
The expected impact is to provide a compatible iOS/Android/W8 applica-
tion, to allow patients with serious cardiologic diseases and in situation of
mobility through Europe to be identified by their own smartphone/tablet and
to access securely and share medical information and images through a user-
friendly interface
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Impact of the recent controversy over statins in France
Anis Saib, Laurent Sabbah, Ludivine Perdrix, Didier Blanchard, Nicolas
Danchin, Etienne Puymirat
Hôpital Européen Georges Pompidou (HEGP), Cardiologie, Paris, 
Background: The effect of statins on the prevention of cardiovascular
events is well demonstrated. However, a recent controversy in France ques-
tioned the interest of statins especially in primary prevention.
Aims: To evaluate the impact of this controversy on patient adherence to
statin therapy and the potential clinical impact.
Methods: All patients on statins were recruited consecutively from consul-
tations over a period of one month (from March 2013) by 5 physicians in
3 centers. Patient demographics and co-morbidities were collected and the
adherence to statin therapy was evaluated with a questionnaire. We estimated
the number of death and major cardiovascular disease (CVD) that could be
induced per year by this controversy from current data.
Results: A total of 142 patients were included: 37 in primary prevention
(mean age 68.0±13.1, 41% women); 105, in secondary prevention (mean age
67.6±12.1, 20% women). In primary prevention, 24.3% of patients intended to
stop statins versus 8.6% in secondary prevention (p<0.001). En France, this
controversy could induce 4992 major CVD, including 1159 additional deaths
in one year whether patients stop really their statins.
Conclusion: Recent controversy over statins could induce a large proportion
of patients to stop their medication and generate a large number of major CVD.
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Coronary artery disease (CAD) risk increases with the elevation of Low-
lipoprotein cholesterol (LDL-c), triglyceride (TG) and low level High-density
lipoprotein cholesterol (HDL-c) levels. A new index called chol-index, in
order to evaluate CAD risk, and investigated its reliability. The aim of this
study was to determine the index and its association with to the risk of devel-
oping CHD in our population.
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Methods: The study included 427 subjects aged 35-70 years with
256 males and females, who underwent diagnostic coronary angiography.
Chol-index was calculated by using a formula as follows: LDL-C-HDL-C (if
TG < 0.4g/l), LDL-C-HDL-C + 1/5 TG (if TG ≥0.4g/l).
Results: The clinical and laboratory characteristics of the study showed
28.43% of patients had CAD and the remaining (71.57%) had normal coronary
artery. The incidence of diabetes mellitus (70% vs 19.5%), hypertension (76.7%
vs 31.9%) and dyslipedimia (26.5% vs 7.7%) was significantly higher in CAD
group compared patients had normal coronary artery. Chol-index was indepen-
dent predictors of CAD. Levels of Chol-index were found significantly higher
in patients had CAD (p=0.019). The logistic regression analysis showed that
Chol-index had a much more significant relation with CAD (OR=2.226,
95%Cl=1.061-4.669; p=0.034) compared with other lipid parameters. A positive
correlation was found between Col-index and the extend and severity of coro-
nary artery disease determined by the Gensini score (r= 0.159; p=0.006).
Conclusion: Chol-index is a simple index which can be used reliably in
prediction of CAD like other lipid parameters in daily clinical practice. 
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Background and objectives: The HTA is a public health problem in
Morocco. According to the national survey (2000) the average prevalence is
33.6% (of which 78% are undiagnosed), and high as 78% from 65 years. The
bread is the staple food in every Moroccan household. Our objective was to
evaluate the amount of salt provided by the consumption of bread in daily
food intake and compared against the recommendations for the consumption
of salt. In order to develop a program of awareness about the impact of over
consumption of salt and its role in causing high blood pressure 
Methodology: quantification of salt by the method MOHR 160 bread sam-
ples (80 with and 80 without salt as control) from 80 bakeries throughout the
city of Casablanca
Results: The average amount used in the preparation of bread is
17.42±1.28 g / kg, which represents a supply of 6.1 g / day of salt in 350g
representing the average daily consumption of bread Moroccans regardless of
other inputs daily of salt
Conclusion: This value alone exceeds both:
• Quantities for sodium established by the Institute of Medicine ( United
States) in 2004 located, according to age, between 1500 and 2300mg / per day
of sodium “3.75 and 5.75 g / per day of salt 
• The therapeutic target of 2000mg / per day of sodium “5g salt” set in
2003 by the World Health Organizations (WHO).
As bread is very much consumed in each meal in Morocco, we can only
recommend using it as a vector for the programmer of awareness about salt
over consumption and hyper blood pressure
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Aim: Two thirds of acute coronary syndromes are incident cases and pri-
mary prevention is of the utmost importance. The aim of this study was to
assess the prevalence of severe hypercholesterolemia (HC) in a preventive car-
diology clinic largely devoted to primary prevention.
Methods: From September 1995 to April 2011, we consecutively included
all the patients (pts) admitted in our preventive cardiology clinic covering an
area of 2.9 millions of inhabitants in Southwestern France. Risk factors,
medical history, drug therapy were recorded and a full lipid profile was
obtained. Secondary prevention was defined as patients having a previous his-
tory of cardiovascular disease.
Results: Among 6629 pts admitted, 4645 pts (70.1%) had a HC (pts on
lipid-lowering drugs or with a LDL-cholesterol (LDL-C) higher than 160 mg/dL).
Among these pts with HC, 27 (0.58%) were untreated pts in primary preven-
tion with LDL-C > 300 mg/dL, 10 (0.22%) were treated HC pts in primary
prevention with LDL-C > 300 mg/dL, 6 (0.13%) were untreated HC in sec-
ondary prevention with LDL-C > 200 mg/dL and 8 (0.17%) were treated HC
in secondary prevention with LDL-C > 200 mg/dL. In these 4 groups, the
majority of pts had lipoprotein(a) > 30 mg/dL (mean lipoprotein(a): 75 mg/dL
in untreated pts in primary prevention with LDL-C > 300 mg/dL; 35 mg/dL
in treated HC pts in primary prevention with LDL-C > 300 mg/dL, 42 mg/dL
in untreated HC in secondary prevention with LDL-C > 200 mg/dL and
51 mg/dL in treated HC in secondary prevention with LDL-C > 200 mg/dL).
Drug treatment varied across the years but combination therapy was quite
uncommon.
Conclusions: In a series of pts admitted in a preventive cardiology clinic,
the prevalence of very severe HC is not rare. Given that our clinic is for a
referral to cardiologists, the real prevalence of unrecognized severe HC is
probably much higher in the population at large.
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Purpose: Fat content of dairy foods is diverse, potentially leading to
varying effects on cardiovascular risk. We studied relationships of low- and
high-fat dairy products with lipids and level of cardiovascular risk.
Methods: A sample of 3078 participants aged 35-64 years, was randomly
selected in 2005-2007. Participants underwent a standardised cardiovascular
risk assessment and were asked to prospectively record the types and amounts
of foods and beverages they consumed over a three-consecutive day period.
Dairy products were separated into two groups: the low-fat group comprised
milk (including milk from desserts and beverages), yogurts and cottage
cheese, whereas other cheeses formed the high-fat group. The SCORE algo-
rithm was used to assess 10-year risk of cardiovascular mortality. 
Results: Forty three percent of the sample had a 10-year risk of cardiovas-
cular mortality ≥2%. After adjustment (including level of education, physical
activity and a diet quality score), the probability of an increased 10-year risk
of cardiovascular mortality (SCORE ≥2%) decreased from the bottom first to
the top fourth quartile (Q) of low-fat dairy product intake: ORQ1(odds ratio)=1;
ORQ2=0.74 [95% confidence interval: 0.60-0.91], ORQ3=0.65 [0.52-0.80], and
ORQ4=0.58 [0.47-0.72] for the first, second, third and fourth quartile, respec-
tively. Intake of low-fat dairy products was inversely associated with low
LDL-cholesterol, but no significant relationship was found with HDL-choles-
terol or triglycerides. None of the lipid parameters was significantly associated
with the consumption of high-fat dairy products. 
Conclusions: Participants with the highest intake of low-fat dairy products
were at the lowest risk of cardiovascular mortality, as assessed by the SCORE
equation, and they exhibited the best LDL-cholesterol profile. Despite exten-
sive adjustment, this observation may still be related to differences in lifestyle
habits. 
